Ken Griffin Chembio Diagnostics, Inc. Call Options Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$0.25 - $0.45 $4,850 - $8,730	-19,400 Reduced 46.75%	22,100 $9,000
Q4 2022 Feb 14, 2023	SELL	$0.2 - $0.33 $320 - $528	-1,600 Reduced 3.71%	41,500 $9,000
Q3 2022 Nov 14, 2022	BUY	$0.35 - $1.1 $8,540 - $26,840	24,400 Added 130.48%	43,100 $16,000

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.